Rama Suresh

Associate Professor of Medicine

    • 991 Citations

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    Breast cancer

    Areas of Clinical Interest

    Clinical oncology, breast cancer, GI malignancies

    Fingerprint Dive into the research topics where Rama Suresh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 19 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    • 991 Citations
    • 18 Article

    FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial

    Park, H., Jin, R. U., Wang-Gillam, A., Suresh, R., Rigden, C., Amin, M., Tan, B. R., Pedersen, K. S., Lim, K. H., Trikalinos, N. A., Acharya, A., Copsey, M. L., Navo, K. A., Morton, A. E., Gao, F. & Lockhart, A. C., 2020, (Accepted/In press) In : JAMA oncology.

    Research output: Contribution to journalArticle

  • Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma

    Grierson, P., Teague, A., Suresh, R., Lim, K. H., Amin, M., Pedersen, K., Tan, B., Huffman, J., Boice, N., Du, L., Liu, J., Lockhart, A. C. & Wang-Gillam, A., Feb 1 2020, In : Journal of Gastrointestinal Oncology. 11, 1, p. 61-67 7 p.

    Research output: Contribution to journalArticle

  • Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia

    Niravath, P., Hilsenbeck, S. G., Wang, T., Jiralerspong, S., Nangia, J., Pavlick, A., Ademuyiwa, F., Frith, A., Ma, C., Park, H., Rigden, C., Suresh, R., Ellis, M., Kent Osborne, C. & Rimawi, M. F., Sep 15 2019, In : Breast Cancer Research and Treatment. 177, 2, p. 427-435 9 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations
    Open Access
  • 10 Scopus citations

    NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

    Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F., Suresh, R., Anderson, K. S., Margenthaler, J., Aft, R., Hobday, T., Moynihan, T., Gillanders, W., Cyr, A., Eberlein, T. J., Hieken, T., Krontiras, H. & 14 others, Guo, Z., Lee, M. V., Spies, N. C., Skidmore, Z. L., Griffith, O. L., Griffith, M., Thomas, S., Bumb, C., Vij, K., Huang Bartlett, C., Koehler, M., Al-Kateb, H., Sanati, S. & Ellis, M. J., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4055-4065 11 p.

    Research output: Contribution to journalArticle

    Open Access
  • 96 Scopus citations